Monday, January 21, 2013

China SFDA proposes to fast track review of drug that fulfils an unmet need

China’s SFDA is considering to make  changes to its drug approval process. SFDA wishes to prioritize the review process, in such a way so as to make sure that Innovative drug candidates, that offers cure or treatment for unmet diseases, should be processed under new fast-track procedures. 
On the other hand, requests for approval of generic drugs that have multiple suppliers would  take longer.


Enter your email address:


Delivered by FeedBurner